[go: up one dir, main page]

Koşaloğlu et al., 2016 - Google Patents

Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases

Koşaloğlu et al., 2016

View PDF @Full View
Document ID
2965160711844435994
Author
Koşaloğlu Z
Zörnig I
Halama N
Kaiser I
Buchhalter I
Grabe N
Eils R
Schlesner M
Califano A
Jäger D
Publication year
Publication venue
Oncoimmunology

External Links

Snippet

Neuroendocrine tumors (NETs) of the gastrointestinal tract are a rare and heterogeneous group of neoplasms with unique tumor biology and clinical management issues. While surgery is the only curative treatment option in patients with early stage NETs, the optimal …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer

Similar Documents

Publication Publication Date Title
Jiang et al. Tumor neoantigens: from basic research to clinical applications
Yang et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses
Villanueva et al. The contribution of epigenetics to cancer immunotherapy
Jiménez-Sánchez et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient
Liu et al. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Gnjatic et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Miller et al. Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival
Bobisse et al. Neoantigen-based cancer immunotherapy
AU2016319316B2 (en) "immune checkpoint intervention" in cancer
Pritchard et al. Exome sequencing to predict neoantigens in melanoma
Leko et al. Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer
Lee et al. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma
Qamra et al. Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma
Zou et al. Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer
WO2021046466A1 (en) Methods, compositions, and systems for profiling or predicting an immune response
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Koşaloğlu et al. Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases
Zolkind et al. Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma
Guang et al. Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
Ji et al. Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy
Dettling et al. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as novel and frequent T-cell targets in human IDH-mutant glioma
JP2020525030A (en) How to assess the suitability of cancer for immunotherapy
Yan et al. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade
Ohue et al. Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody
GuhaThakurta et al. Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome